% | $
Quotes you view appear here for quick access.

PROLOR Biotech, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • avav1001 avav1001 Nov 17, 2012 3:05 PM Flag

    Summer' analyst

    From Motley Fool 11/16/2012, "Biotech M&A has risen to a 4-year high as drug manufacturers rush to find solutions to multi-billion dollar patent cliffs. AstraZeneca's decision, for example, to delay share buybacks has renewed market speculation ... Other promising developers, like PROLOR Biotech, Dendreon, and Pharmacyclics, have been rumored to be on the takeover screens of large companies. While Dendreon is focused on cancer treatments, PROLOR is developing what is expected to be the first long-acting version of hGH. An acquisition of either firms would generate meaningful revenue synergies for an acquirer promoting to to larger patient populations."

    Sentiment: Buy